Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.

The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.

In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time—making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.

Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.

Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.

The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.

The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region’s fastest growth during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1—44%, Tier 2—32%, and Tier 3—24%
• By Designation: (Managers)—45%, (CXOs, Directors)—30%, and (Executives)—25%
• By Region: North America—40%, Europe—25%, Asia-Pacific—20%, Rest of the World—15%

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• PacBio (US)
• Oxford Nanopore Technologies PLC (UK)
• 10X Genomics (US)
• QIAGEN (Netherlands)
• Agilent Technologies (US)
• Danaher Corporation (US)
• Takara Bio Inc. (Japan)
• Adaptive Biotechnologies (US)
• BGI Group (China)
• Tecan Trading AG (Switzerland)
• Azenta US Inc. (US)
• Personalis, Inc. (US)
• Creative Biolabs (US)
• Celemics, Inc. (South Korea)
• CellCarta (Canada)
• iRepertoire, Inc. (US)
• New England Biolabs (US)
• Cerba Research (Belgium)
• CeGat GmbH (Germany)
• Element Biosciences (US)
• Seqalis (Belgium)
• Synbio Technologies (China)
• MedGenome (US)
• Enpicom (Netherlands)

Research Coverage:

This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product–end user, service–end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.

Reasons to Buy this Report :

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.
• Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market
• Market Development: Comprehensive information about lucrative markets – the report analyses the immune repertoire sequencing market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.